Abstract
Thalidomide at doses >200 mg has 100% grade 1-2 and 25% grade 3-4 toxicities requiring discontinuation. We report a retrospective study of relapsed myeloma patients treated with thalidomide 200 mg with no dose escalation. Thirty patients were identified; 43% of patients responded with paraprotein decline >75% - 2 (6%), 50-75% - 7 (23%), 25-50% - 4 (14%) and 2 (6%) were stable. All five patients with 13q deletion responded. Only 54% reported grade 1-2 toxicities (none reporting > grade 2) with 5 (17%) discontinuing treatment due to toxicity. Thalidomide 200 mg daily with no dose escalation appears as effective and better tolerated than escalated doses for relapsed myeloma patients.
Original language | English (US) |
---|---|
Pages (from-to) | 1147-1149 |
Number of pages | 3 |
Journal | Leukemia and Lymphoma |
Volume | 44 |
Issue number | 7 |
DOIs | |
State | Published - Jul 1 2003 |
Keywords
- Dose escalation
- Efficacy
- Intermediate dose
- Thalidomide
ASJC Scopus subject areas
- Hematology
- Oncology
- Cancer Research